Avalanche Biotechnologies Boosts IPO As 2 More Biotechs Go Public This Week

Published: Jul 22, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Blindness drug developer Avalanche Biotechnologies Inc. boosted its IPO target to $93 million from $86 million, hoping to sell 6.2 million shares at $13 to $15 per share.

In addition, the Menlo Park gene therapy company will receive $10 million from partner and part-owner Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) from a private placement of stock, the company said in a Securities and Exchange Commission filing Monday.

Help employers find you! Check out all the jobs and post your resume.

Back to news